By SPC News Staff
The FDA expanded the indication of ivacaftor (Kalydeco, Vertex Pharmaceuticals), tripling the number of rare gene mutations that the cystic fibrosis drug can now treat.
Ivacaftor is now indicated for use in people with CF aged 2 years and older who have one of 33 residual function mutations in the CF transmembrane conductance regulator (CFTR) gene.